Daniel L. Mulkerin

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

T. Greten, G. Wilding, J. Kolesar, 2016, Investigational New Drugs.